A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival

Nicholas P. Schaub,Meghna Alimchandani,Martha Quezado,Phil Kalina,John Eberhardt,Marybeth S. Hughes,Tatiana Beresnev,Raffit Hassan,David L. Bartlett,Steven K. Libutti,James F. Pingpank,Richard E. Royal,Udai S. Kammula,Prakash Pandalai,Giao Q. Phan,Alexander Stojadinovic,Udo Rudloff,H. Richard Alexander,Itzhak Avital

A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival

2013

Nicholas P. Schaub
Meghna Alimchandani
Martha Quezado
Phil Kalina
John Eberhardt
Marybeth S. Hughes
Tatiana Beresnev
Raffit Hassan
David L. Bartlett
Steven K. Libutti
James F. Pingpank
Richard E. Royal
Udai S. Kammula
Prakash Pandalai
Giao Q. Phan
Alexander Stojadinovic
Udo Rudloff
H. Richard Alexander
Itzhak Avital

Background Malignant peritoneal mesothelioma (MPM) is a rare disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Estimation of personalized survival times can potentially guide treatment and surveillance.

Keywords:

Hyperthermic intraperitoneal chemotherapy
Peritoneal mesothelioma
General surgery
Nomogram
Oncology
Rare disease
Malignant Peritoneal Mesothelioma
Peritoneal Carcinomatosis Index
Medicine
Internal medicine
Survival rate
Peritoneal Neoplasm
Fluorouracil
Mesothelioma
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations